Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A18 trial of pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer
CTR20201460Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in Cervical Cancer (CC), sponsored by Merck & Co.. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20201460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201460.